Trametinib and everolimus for recurrent gliomas
Treatments studied
Part of Cancer clinical trials.
This trial tests two drugs, trametinib and everolimus, for children and young adults with recurrent or progressive gliomas (a type of brain tumor). The goal is to see if this drug combination is safe and effective in treating these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with a low-grade or high-grade glioma that has returned or progressed after prior treatment.
- Completed previous therapy (chemotherapy, radiation, or other drugs) and recovered from side effects.
- Able to provide a tumor tissue sample for genetic testing, or have had such testing done already.
- Have a performance status score (Karnofsky or Lansky) of at least 50, indicating a moderate level of physical ability.
- Adequate organ function, including blood cell counts, liver and kidney function, and heart and lung health.
- Not taking certain medications that could interact with the study drugs.
- For women of childbearing age, a negative pregnancy test prior to enrollment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
This trial is testing a combination of two drugs, vinblastine and tovorafenib, for children and young adults (up to age 25) whose low-grade glioma has come back or worsened after prior treatment. It is for people whose tumor has a specific change in a gene called BRAF or CRAF.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This Phase 2 trial studies whether a targeted medicine that blocks MEK can work better than chemotherapy for certain slow-growing brain tumors in children. You may qualify if your tumor has specific genetic features and has not already been treated with non-surgery therapies.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
Hear when a new Low-grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.